General and Minimally Invasive Surgery Unit, Cristo Re Hospital, Rome, Italy.
Eur Rev Med Pharmacol Sci. 2020 Oct;24(20):10696-10702. doi: 10.26355/eurrev_202010_23428.
Percutaneous cholecystostomy (PC) is used for the treatment of acute cholecystitis in patients with high surgical risk due to the severity of cholecystitis and/or the underlying acute or chronic medical comorbidities. The evidence for this strategy is unclear.
We searched PubMed and the Cochrane databases for English-language studies published from January 1979 through December 31, 2019, for randomized clinical trials (RCTs), meta-analyses, systematic reviews, and observational studies.
The two randomized studies that have compared PC with cholecystectomy (CCY) or conservative treatment have shown that the clinical outcomes did not differ significantly between the groups. Similar results have been found in the large majority of retrospective cohorts or single-center studies that have compared PC with CCY.
PC does not seem to offer any benefit compared with CCY in the treatment of acute cholecystitis in patients with high surgical risk due to the severity of cholecystitis and/or the underlying acute or chronic medical comorbidities. A large, prospective, randomized study that compares percutaneous PC and CCY in patients with high surgical risk and/or moderate to severe cholecystitis is warranted.
经皮胆囊造口术(PC)用于治疗因胆囊炎严重程度和/或潜在的急性或慢性合并症而手术风险较高的患者的急性胆囊炎。这种治疗策略的证据尚不清楚。
我们检索了 1979 年 1 月至 2019 年 12 月 31 日发表的英文随机临床试验(RCT)、荟萃分析、系统评价和观察性研究的 PubMed 和 Cochrane 数据库。
两项比较 PC 与胆囊切除术(CCY)或保守治疗的随机研究表明,两组的临床结局无显著差异。在大多数比较 PC 与 CCY 的回顾性队列或单中心研究中也发现了类似的结果。
对于因胆囊炎严重程度和/或潜在的急性或慢性合并症而手术风险较高的患者,PC 与 CCY 相比似乎没有任何优势。因此,需要一项比较高手术风险和/或中度至重度胆囊炎患者的经皮 PC 和 CCY 的大型前瞻性随机研究。